Eli Lil­ly gets a short cut at FDA for abe­maci­clib; Ca­lyxt files for $100M IPO

⇨ Look­ing to play catch-up with the lead­ers in the CDK 4/6 can­cer field, Eli Lil­ly scored the in­side track at the FDA for abe­maci­clib, now un­der re­view for breast can­cer. The agency is giv­ing the drug a pri­or­i­ty re­view, shav­ing four months off the agency’s re­view sched­ule. “We are pleased that the FDA has grant­ed abe­maci­clib Pri­or­i­ty Re­view, both as a po­ten­tial monother­a­py and com­bi­na­tion ther­a­py [with ful­ves­trant] for pa­tients with ad­vanced breast can­cer,” said Levi Gar­raway, se­nior vice pres­i­dent, glob­al de­vel­op­ment and med­ical af­fairs, Lil­ly On­col­o­gy.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER